25th Anniversary International Scientific Conference-2016

Permanent URI for this collectionhttp://repository.kln.ac.lk/handle/123456789/12769

Plenaries, Symposia and free papers presented at the 25th Anniversary International Scientific Conference, held on 6-8th April 2016, Faculty of Medicine, University of Kelaniya to celebrate the Silver Jubilee Anniversary of Faculty of Medicine

Browse

Now showing 1 - 2 of 2

Cancer antigen 15-3 and the grade of the breast carcinoma in newly diagnosed patients
(Faculty of Medicine, University of Kelaniya, Sri Lanka, 2016) Akalanka, H.M.K.; Ekanayake, S.; Samarasinghe, K.
BACKGROUND: Cancer antigen 15-3 (CA15-3) is a breast tumor marker of clinical utility. However, the utility of measuring CA15-3 in patients with breast cancer (BC) remains controversial. OBJECTIVES: To assess CA15-3 concentrations of newly diagnosed BC patients and to compare those with concentrations of apparently healthy females and within the different the grades of the carcinoma. METHODS: CA15-3 concentration of newly diagnosed BC patients (n=155) and apparently healthy age matched females (n=35) was assessed using enzyme immunoassay sandwich method with a final fluorescent detection using mini vidas immuno analyser. Nottingham grade of the carcinoma of each BC patient was recorded from the histopathology records. RESULTS: The median levels of CA15-3 of the BC patients and apparently healthy women in the study sample was 14.45 (IQR: 10.17) U/mL and 14.19 (IQR: 7.09) U/mL respectively. CA15-3 concentrations were not significantly different among BC and healthy women (p>0.05). Only 11% of women with BC had elevated CA15-3 concentrations above the reference range (30 U/mL). The BC patients were classified as Nottingham grade I (13.4%), II (47.8%) and III (38%). CA15-3. Concentrations (median and IQR) within each grade were 15.24 (6.62), 13.06 (11.56) and 17.52 (13.69) respectively. CA15-3 concentrations were not significantly different according to the grade (p>0.05). CONCLUSIONS: CA 15-3 concentrations of newly diagnosed breast cancer patients were not significantly different when compared with apparently healthy women and according to the Nottingham grading.
Role of Cancer antigen 15.3 in the pre-operative assessment of primary breast cancer
(Faculty of Medicine, University of Kelaniya, Sri Lanka, 2016) Peiris, H.H.; Mudduwa, L.K.B.; Wijeratne, W.M.D.G.B.; Liyanage, T.G.; Liyanage, N.C.; Gunasekara, S.N.; Kaushalya, M.H.A.
BACKGROUND: Cancer antigen (CA) 15.3 is the most commonly used tumour marker in predicting recurrence of breast cancer. The role of pre-operative CA 15.3 in the assessment of breast cancer has not been substantiated yet. OBJECTIVE: To determine the role of CA 15.3 in the pre-operative assessment of breast cancer patients METHODS: All patients who were diagnosed of primary breast cancer and underwent surgery at a tertiary-care hospital from April 2014 to October 2015 were enrolled. Serum level of CA 15.3 was assessed on a pre-operative blood sample by ELISA and ≥30 U/ml was considered as the cut off as defined by the manufacturer’s literature. The association of CA 15.3 levels with the clinico-pathological parameters was analyzed with chi-square test. RESULTS: Of the 150 patients (mean age 56.83 [SD=13.39] years) enrolled, majority (85.6%) had grade 2/3 tumours with lymph node metastasis (58.2%) at the time of presentation. None had distant metastasis. Elevated pre-operative serum level of CA 15.3 was detected in 34% of patients who had more estrogen receptor negative(43.13%), progesterone receptor negative (50.98%) and triple negative(29.1%) tumours compared to those without elevated pre-operative CA 15.3 (p=0.017,0.036 and 0.001 respectively). There was no association with other clinico-pathological features. CONCLUSIONS: Pre-operative serum level of CA15.3 is elevated only in one third of breast cancer patients. Elevated pre-operative CA 15.3 has a prognostic value as it is elevated mostly in the hormone receptor negative and triple negative breast cancers predicting a poor prognosis.